Home LiteratureArticle Details
PMID: 10699955 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha.

International journal of cancer ·Vol. 85 ·No. 5 ·2000-03-01 ·Pages 720-5

Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, Heim MH

Abstract

Advanced malignant melanoma is an aggressive malignancy with poor prognosis. Current therapeutic strategies have a modest success rate. The most promising treatment consists of a combination of chemotherapy with interferon-alpha, but complete response rates remain less than 15%. Interferon-alpha is also effective in adjuvant therapy for non-advanced melanoma treated surgically. The molecular mechanisms leading to loss of growth restraints and gain of growth-promoting functions during carcinogenesis of malignant melanoma are not understood in detail. Here, we studied 9 human melanoma cell lines with regard to growth inhibition by interferon-alpha and defects in intracellular signal transduction through the Jak-STAT pathway. In 3 cell lines, we found a complete loss of growth restraint by interferon-alpha. In all of them, different components of the Jak-STAT pathway were defective. Since signal transduction through the Jak-STAT pathway is necessary for antiviral and antiproliferative effects of interferons, we conclude that defects in this pathway may be one of the mechanisms that lead to cancer progression through loss of growth-restraining functions. Moreover, our results indicate that a subgroup of melanomas could be completely resistant to interferon-alpha and should therefore not be treated with this cytokine.

MeSH Terms
Cell Division/drug effects Chromosome Aberrations Chromosome Mapping DNA-Binding Proteins/metabolism Humans Interferon-alpha/toxicity Janus Kinase 1 Karyotyping Lymphatic Metastasis Male Melanoma/genetics,pathology,physiopathology Middle Aged Protein-Tyrosine Kinases/metabolism Proteins/metabolism Receptor, Interferon alpha-beta Receptors, Interferon/physiology STAT1 Transcription Factor STAT2 Transcription Factor STAT3 Transcription Factor Signal Transduction/drug effects TYK2 Kinase Trans-Activators/metabolism Tumor Cells, Cultured
Chemicals
DNA-Binding Proteins Interferon-alpha Proteins Receptors, Interferon STAT1 Transcription Factor STAT1 protein, human STAT2 Transcription Factor STAT3 Transcription Factor STAT3 protein, human Trans-Activators Receptor, Interferon alpha-beta Protein-Tyrosine Kinases JAK1 protein, human Janus Kinase 1 TYK2 Kinase TYK2 protein, human
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Pansky A
Department of Research, University Hospital Basel, Basel, Switzerland.
Hildebrand P
Fasler-Kan E
Baselgia L
Ketterer S
Beglinger C
Heim M H
Article Info
Journal
International journal of cancer
Abbr.
Int J Cancer
ISSN
0020-7136
Published
2000-03-01
Pages
720-5
Language
English
Region
United States
NLM ID
0042124
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com